Nektar Therapeutics (NKTR) Files Form 4 Insider Selling : Jillian B. Thomsen Sells 100,000 Shares

Nektar Therapeutics (NKTR): Jillian B. Thomsen , SVP & Chief Accounting Officer of Nektar Therapeutics sold 100,000 shares on Jul 11, 2016. The Insider selling transaction was reported by the company on Jul 13, 2016 to the Securities and Exchange Commission. The shares were sold at $15.09 per share for a total value of $1,509,000.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 5, 2016, Robert Chess (director) sold 5,000 shares at $14.10 per share price.On May 18, 2016, John Nicholson (SVP & Chief Financial Officer) sold 856 shares at $13.58 per share price.Also, On May 18, 2016, Ivan P. Gergel (SVP & Chief Medical Officer) sold 432 shares at $13.58 per share price.On May 18, 2016, Howard W Robin (President & CEO) sold 2,170 shares at $13.58 per share price.

Nektar Therapeutics: On Monday, Jul 11, 2016 heightened volatility was witnessed in Nektar Therapeutics which led to swings in the share price. The shares opened for trading at $15.06 and hit $15.21 on the upside , eventually ending the session at $15.07, with a gain of 1.01% or 0.15 points. The heightened volatility saw the trading volume jump to 7,08,689 shares. The 52-week high of the share price is $17.55 and the company has a market cap of $2,053 M . The 52-week low of the share price is at $9.16.

Nektar Therapeutics Money Flow Index Chart

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company’s pipeline is comprised of drug candidates for therapeutic areas including oncology pain anti-infectives and immunology. The Company’s research and development activities involve small molecule drugs peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics pharmacodynamics half-life bioavailability metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics including small molecule oral and parenteral drugs proteins peptides and antibody fragments.

Leave a Reply

Nektar Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Nektar Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.